HealthDay News — Relaxation and stress management techniques have short-term beneficial effects for people with hypertension, according to a systematic review and network meta-analysis published ...

Ed Martin, the Interim US Attorney for the District of Columbia, has sent out a letter to a rather obscure medical journal, "Chest" - a journal published ...

To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The new analysis, they note, further verifies that while the use of either e-cigarettes or traditional “combustible” ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...